FindTrial
Sign In

Genetic variation in STAT4 predicts response to nucleos(t)ide analogues therapy for hepatitis B e antigen-positive chronic hepatitis B: a prospective, open, controlled multi-center study

Genetic variation in STAT4 predicts response to nucleos(t)ide analogues therapy for hepatitis B e antigen-positive chronic hepatitis B: a prospective, open, controlled multi-center study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-RPC-16009346
Enrollment
Unknown
Registered
2016-10-08
Start date
2017-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

DNA type: nucleos(t)ide analogues therapy

Sponsors

Shanghai Public Clinical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: HBeAg(+)chronic hepatitis B patients

Exclusion criteria

Exclusion criteria: combined other hepatitis patients

Design outcomes

Primary

MeasureTime frame
The ratio of HBeAg seroconvention;—

Secondary

MeasureTime frame
The ratio of HBeAg clearance;The ratio of HBVDNA clearance;—

Countries

China

Contacts

Public ContactQi Xun

Shanghai Public Clinical Center

qixun@shaphc.org+86 18916121139

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026